Accueil / Communiqués / Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

Thursday, February 28th 2019 at 12:00pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today joins forces with 30
million healthcare advocates around the world for the 12th Annual Rare
Disease Day®, an awareness day dedicated to elevating public
understanding of rare diseases and calling attention to the special
challenges people living with rare diseases face.

“Despite important scientific advances in the treatment of rare
diseases, there remains significant work to be done to help patients and
families. At Ra Pharma, we are focused on developing medicines to treat
patient populations with complement-mediated diseases and are committed
to expanding patient access to more convenient life-saving medicines,”
said Doug Treco, Ph.D., President and Chief Executive Officer of Ra
Pharma. “In 2018, we made important progress in achieving this goal, as
we successfully completed a Phase 2 clinical trial for our lead
compound, zilucoplan, in generalized myasthenia gravis. As we prepare to
initiate a Phase 3 clinical program for this indication, we also
continue to advance our broader pipeline of therapeutic candidates for
the treatment of rare, complement-mediated diseases.”

Dr. Treco added: “One of the privileges of being at a research-based
company like ours is working side-by-side with families and patients who
are battling rare diseases. This Rare Disease Day, we extend our
appreciation to these families and patients for their bravery, tenacity,
and strength. It’s an honor to be a part of their lives, and they
inspire us to do our best work every day.”

According to the National Institutes of Health, there are more than
6,000 rare diseases known today that affect an estimated 25 million
people in the United States. In the U.S., a disease is defined as rare
if it affects fewer than 200,000 people.

About Rare Disease Day

Rare Disease Day takes place every year on the last day of February to
raise awareness amongst the general public and decision-makers about
rare diseases and their impact on patients’ lives. It was established in
2008 by EURORDIS, the organization representing rare disease patients in
Europe, and is now observed in more than 80 nations. In the U.S., Rare
Disease Day is sponsored by the National Organization for Rare Disorders
(NORD®), the largest and leading independent, non-profit
organization committed to the identification, treatment, and cure of
rare diseases.

For more information about Rare Disease Day in the U.S. and to search
for information about rare diseases, visit NORD’s website, www.rarediseaseday.us.
For information about global activities, go to www.rarediseaseday.org.

About Zilucoplan (formerly RA101495 SC)

Ra Pharma is developing zilucoplan for generalized myasthenia gravis
(gMG), paroxysmal nocturnal hemoglobinuria (PNH), and other
complement-mediated disorders. The product candidate is designed for
convenient, once-daily subcutaneous self-administration. Zilucoplan is a
synthetic, macrocyclic peptide discovered using Ra Pharma’s powerful
proprietary drug discovery technology. The peptide binds complement
component 5 (C5) with sub-nanomolar affinity and allosterically inhibits
its cleavage into C5a and C5b upon activation of the classical,
alternative, or lectin pathways. By binding to a region of C5
corresponding to C5b, zilucoplan is additionally designed to disrupt the
interaction between C5b and C6 and prevent assembly of the membrane
attack complex. This activity may define an additional, novel mechanism
for the inhibition of C5 function.

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
complement-mediated diseases. The Company discovers and develops
peptides and small molecules to target key components of the complement
cascade. For more information, please visit: www.rapharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding expanding patient
access to more convenient life-saving medicines and our plans to
initiate a Phase 3 clinical program for zilucoplan in generalized
myasthenia gravis. All such forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include
the risks that Ra Pharma’s product candidates, including zilucoplan,
will not successfully be developed or commercialized, in the timeframe
we expect or at all; the risk that USAN does not approve the name
zilucoplan; as well as the other factors discussed in the “Risk Factors”
section in Ra Pharma’s most recently filed Annual Report on Form 10-K,
as well as other risks detailed in Ra Pharma’s subsequent filings with
the Securities and Exchange Commission. There can be no assurance that
the actual results or developments anticipated by Ra Pharma will be
realized or, even if substantially realized, that they will have the
expected consequences to, or effects on, Ra Pharma. All information in
this press release is as of the date of the release, and Ra Pharma
undertakes no duty to update this information unless required by law.

Contacts

Investors:
Ra Pharmaceuticals, Inc.
Natalie Wildenradt,
617-674-9874
nwildenradt@rapharma.com

Media:
Argot
Partners
David Rosen, 212-600-1902
david.rosen@argotpartners.com

Source: Ra Pharmaceuticals, Inc.


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …